Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin

The document describes a case series involving three postmenopausal women with hyperandrogenism and virilization symptoms, including androgenetic alopecia and hirsutism, who were treated with the GnRH agonist leuprorelin. This treatment led to a decrease in testosterone levels, confirming the ovarian source of the excess androgens. The outcomes varied, with one patient showing limited improvement in alopecia and another maintaining normal testosterone levels post-treatment. The study suggests that long-term GnRH agonist treatment could be a viable alternative to bilateral oophorectomy for managing hyperandrogenism in postmenopausal women, particularly for those at increased surgical risk or who prefer not to have surgery. However, the study acknowledges the need for more clinical data to determine the optimal duration of treatment.